Peptide and Anticoagulant Drugs Market Research Report – Forecast to 2023

Peptide and Anticoagulant Drugs Market Research Report – Forecast to 2023

ID: MRFR/HC/4926-HCRR | | Region: Global | 100 pages | Half-Cooked Research Reports

Global Peptide and Anticoagulant Drugs Market Research Report, by Type (Antibiotic, ACE Inhibitor, and Glatiramer Acetate), Application (Diabetes and Cancer) End Users (Hospital and Clinics, Research Centers, Diagnostic Center) – Global Forecast Till 2023


Market Scenario


Anticoagulants are referred to as blood thinners. It is a chemical substance that prevents or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals, it helps to keep the bitten area unclotted long enough for the animal to obtain some blood. Anticoagulants are related to and thrombolytic drugs and antiplatelet drugs by manipulating the various pathways of blood coagulation which inhibit platelet aggregation. These drugs are majorly used for deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. Peptides are long chain amino acids.  Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of this market. Also, an increase in the rate of Diabetes and Cancer promotes the growth of the market. According, to WHO in 2017 diabetes patients has risen from 108 million in 1980 to 422 million in 2014. Global prevalence of diabetes in adults over 18 years of age has increased from 4.7% in 1980 to 8.5% in 2014. Also predicted that breast cancer rates are highest in non-Hispanic white women, breast cancer death rates are highest in African American women which increase the growth of peptide and anticoagulant drugs market in the forecast period.  However, the higher price of NOACs and lack of antidots for NOACs impede the market growth.


Segmentation


The global peptide and anticoagulant drugs market is segmented on the basis of type, application and end users. The peptide and anticoagulant drugs market by type is hormonal, antibiotic, ACE inhibitor antifungal, other peptide drugs, and anticoagulants. Hormonal is sub-segmented into categorized into insulin teriparatide and leuprolide acetate. Antibiotic is categorized into eptifibatide and warfarin. On the basis of anticoagulants, the market is sub-segmented into enoxaparin sodium and heparin sodium. and on the basis of application, the market is sub-segmented into diabetes, cancer, infectious diseases, cancer, osteoporosis, cardiology, gynecology, other. On the basis of end users, the market is segmented into hospitals, research centers, and diagnostic centers.


On the basis of region, the global peptide and anticoagulant drugs market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. According to the cancer organization in 2017, it was found that 63,410 new cases of breast carcinoma in situ, 252,710 new cases of invasive breast cancer, and 40,610 breast cancer deaths.


 The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players for peptide and anticoagulant drugs market


Some of the key players in the global peptide drugs market are Abbott Laboratories (U.S.), Cadila Pharmaceuticals (India), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), and Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India).


Regional Market Summary  


Global Peptide and Anticoagulant Drugs Market Share (%), by Region, 2017


Peptide and Anticoagulant Drugs Market Share


Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health


It is estimated that North America dominated the global peptide and anticoagulant drugs market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. According, to WHO in it was estimated that diabetes was the cause of 1.6 million deaths. Most of all deaths related to high blood glucose occur before the age of 70 years. WHO also projected that diabetes will be the seventh leading cause of death in 2030 which can be the major leading factor in the growth of peptide and anticoagulant drugs market in this region.


Europe stood second largest in the peptide and anticoagulant drugs market owing to the increasing use of tobacco. According to the Cancer Research UK, 359,960 cases of cancer were found in 2015. Also, 35,620 deaths caused due to lung cancer in this region due to change in lifestyle which can enhance the growth of peptide and anticoagulant drugs market.


Asia-Pacific was projected to be the fastest growing region for the global peptide and anticoagulant drugs market in 2017. The market is expected to witness growth owing to the rising prevalence of cancer, changing lifestyle, and increasing tobacco use within the population. The international diabetes federation estimated 72,946,400 cases of diabetes in India in 2017. Such a high incidence of diabetes cases favors the market growth in this region.


The Middle East and Africa holds the least share in the global peptide and anticoagulant drugs market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.


Intended Audience



  • Pharmaceutical companies

  • Peptide and anticoagulant drugs manufacturers

  • Peptide and anticoagulant drugs marketing players

  • Peptide and anticoagulant drugs distributors

  • Various research and consulting companies


Market Segmentation


Global Peptide and anticoagulant drugs Market, by Type



  • Hormonal

  • Insulin

  • Teriparatide

  • Leuprolide Acetate

  • Antibiotic

  • Eptifibatide

  • Warfarin



  • ACE Inhibitor

  • Antifungal

  • Other Peptide Drugs

  • Anticoagulants

  • Enoxaparin Sodium

  • Heparin Sodium

  • Others


Global Peptide and anticoagulant drugs Market, by Application



  • Diabetes

  • Infectious Diseases

  • Cancer

  • Osteoporosis

  • Cardiology

  • Gynecology

  • Others


Global Peptide and anticoagulant drugs Market, by End-Users



  •  Introduction

  •  Hospitals and clinics

  • Research Centers

  • Diagnostic Centers


Global Peptide and Anticoagulant Drugs Market, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Peptide and anticoagulant drugs Market, by Type

6.1 Introduction

6.2 Hormonal

6.2.1 Insulin

6.2.2 Teriparatide

6.2.3 Leuprolide Acetate

6.3 Antibiotic



6.3.1 Eptifibatide



6.3.2 Warfarin





6.4 ACE Inhibitor

6.5 Antifungal

6.6 Other Peptide Drugs

6.7 Anticoagulants

6.7.1 Enoxaparin Sodium



6.7.2 Heparin Sodium

6.7.3 Others



Chapter 7. Global Peptide and anticoagulant drugs Market, by Application

7.1 Introduction

7.2 Diabetes

7.3 Infectious Diseases

7.4 Cancer

7.5 Osteoporosis

7.6 Cardiology

7.7 Gynecology

7.8 Others





Chapter 8. Global Peptide and anticoagulant drugs Market, by End-Users

8.1 Introduction

8.2 Hospitals and clinics

8.3 Research centers

8.4 Diagnostic Centers



Chapter 9. Global Peptide and anticoagulant drugs Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Abbott Laboratories Company

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 Cadila Pharmaceuticals

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Sanofi S.A.

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Eli Lilly and Company

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Cipla Limited

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Biocon Limited

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Intas Pharmaceuticals Ltd.

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Lupin Limited

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Emcure Pharmaceuticals Ltd.

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Sun Pharmaceutical Industries Ltd

11.10.1 Overview

11.10.2 Type Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Novartis International AG

11.11.1Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis



11.12 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Global Peptide and anticoagulant drugs Market Industry Synopsis, 2018–2023

Table 2 Global Peptide and anticoagulant drugs Market Estimates & Forecast, 2018–2023, (USD Million)

Table 3 Global Peptide and anticoagulant drugs Market, by Region, 2018–2023, (USD Million)

Table 4 Global Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)

Table 5 Global Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)

Table 6 Global Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)

Table 7 North America: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)

Table 8 North America: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)

Table 9 North America: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)

Table 10 US: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)

Table 11 US: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)

Table 12 US: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)

Table 13 Canada: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)

Table 14 Canada: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)

Table 15 Canada: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)

Table 16 South America: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)

Table 17 South America: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)

Table 18 South America: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)

Table 19 Europe: Peptide and anticoagulant drugs Market, Type, 2018–2023, (USD Million)

Table 20 Europe: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)

Table 21 Europe: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)

Table 22 Western Europe: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)

Table 23 Western Europe: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)

Table 24 Western Europe: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)



Table 25 Eastern Europe: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)

Table 26 Eastern Europe: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)

Table 27 Eastern Europe: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)

Table 28 Asia-Pacific: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)

Table 29 Asia-Pacific: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)

Table 30 Asia-Pacific: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)

Table 31 Middle East & Africa: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)

Table 32 Middle East & Africa: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)

Table 33 Middle East & Africa: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)





LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Peptide and anticoagulant drugs Market

Figure 3 Market Dynamics for the Global Peptide and anticoagulant drugs Market

Figure 4 Global Peptide and anticoagulant drugs Market Share, by Type 2017

Figure 6 Global Peptide and anticoagulant drugs Market Share, by Application, 2017

Figure 6 Global Peptide and anticoagulant drugs Market Share, by End-User, 2017

Figure 7 Global Peptide and anticoagulant drugs Market Share, by Region, 2017

Figure 8 North America Peptide and anticoagulant drugs Market Share, by Country, 2017

Figure 9 Europe Prescribed Health Apps Share, by Country, 2017

Figure 10 Asia-Pacific Peptide and anticoagulant drugs Market Share, by Country, 2017

Figure 11 Middle East & Africa Peptide and anticoagulant drugs Market Share, by Country, 2017

Figure 12 Global Peptide and anticoagulant drugs Market: Company Share Analysis, 2017 (%)

Figure 13 Abbott Laboratories Company: Key Financials

Figure 14 Abbott Laboratories Company: Segmental Revenue

Figure 15 Abbott Laboratories Company: Geographical Revenue

Figure 16 Cadila Pharmaceuticals .: Key Financials

Figure 17 Cadila Pharmaceuticals .: Segmental Revenue

Figure 18 Cadila Pharmaceuticals .: Geographical Revenue

Figure 19 Sanofi S.A.: Key Financials

Figure 20 Sanofi S.A.: Segmental Revenue

Figure 21 Sanofi S.A.: Geographical Revenue

Figure 22 Eli Lilly and Company: Key Financials

Figure 23 Eli Lilly and Company: Segmental Revenue

Figure 24 Eli Lilly and Company: Geographical Revenue

Figure 25 Cipla Limited: Key Financials

Figure 26 Cipla Limited: Segmental Revenue

Figure 27 Cipla Limited: Geographical Revenue

Figure 28 Biocon Limited: Key Financials

Figure 29 Biocon Limited: Segmental Revenue

Figure 30 Biocon Limited: Geographical Revenue

Figure 31 Intas Pharmaceuticals Ltd.: Key Financials

Figure 32 Intas Pharmaceuticals Ltd.: Segmental Revenue

Figure 33 Intas Pharmaceuticals Ltd.: Geographical Revenue

Figure 34 Lupin Limited: Key Financials

Figure 35 Lupin Limited: Segmental Revenue

Figure 36 Lupin Limited: Geographical Revenue

Figure 37 Emcure Pharmaceuticals Ltd.. : Key Financials

Figure 38 Emcure Pharmaceuticals Ltd.: Segmental Revenue

Figure 39 Sun Pharmaceutical Industries Ltd.: Key Financials

Figure 40 Sun Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 41 Sun Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 42 Novartis International AG: Key Financials

Figure 43 Novartis International AG: Segmental Revenue

Figure 44 Novartis International AG: Geographical Revenue